ArQule, Inc.

( )
ARQL After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
MYOKMyoKardia, Inc. -0.03%221.941.8%$508.69m
CTLTCatalent, Inc. -1.28%91.222.1%$214.11m
HZNPHorizon Therapeutics Plc -1.47%78.465.8%$161.48m
JAZZJazz Pharmaceuticals Plc -1.50%147.722.4%$141.60m
VRXValeant Pharmaceuticals International, Inc. 0.58%17.2114.1%$101.27m
SAVACassava Sciences, Inc. -6.11%9.840.0%$90.32m
BHCBausch Health Cos., Inc. 0.58%17.210.0%$69.44m
ICLRICON plc 0.06%204.004.3%$51.21m
SAGESAGE Therapeutics, Inc. 0.91%69.728.6%$45.08m
ARGXargenx SE -2.12%264.170.0%$44.83m
ZGNXZogenix, Inc. -1.08%20.187.5%$42.77m
AMRNAmarin Corp. Plc -2.33%5.031.5%$40.00m
UTHRUnited Therapeutics Corp. 1.28%116.4714.1%$39.71m
ENDPEndo International Plc 13.25%5.648.7%$36.75m
PRGOPerrigo Co. Plc -3.69%45.636.8%$35.58m

Company Profile

ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employs technologies, such as its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs. The Company's product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ 197 is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in Microphthalmia Transcription Factor (MiT) associated tumors, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma and hepatocellular carcinoma (HCC). The Company has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) in the United States, Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin).